Titlebook: Cancer Biology and Advances in Treatment; Phuc Van Pham Conference proceedings 2020 Springer Nature Switzerland AG 2020 BRCA gene.breast c

incontestable

书目名称Cancer Biology and Advances in Treatment影响因子(影响力)




书目名称Cancer Biology and Advances in Treatment影响因子(影响力)学科排名




书目名称Cancer Biology and Advances in Treatment网络公开度




书目名称Cancer Biology and Advances in Treatment网络公开度学科排名




书目名称Cancer Biology and Advances in Treatment被引频次




书目名称Cancer Biology and Advances in Treatment被引频次学科排名




书目名称Cancer Biology and Advances in Treatment年度引用




书目名称Cancer Biology and Advances in Treatment年度引用学科排名




书目名称Cancer Biology and Advances in Treatment读者反馈




书目名称Cancer Biology and Advances in Treatment读者反馈学科排名

慷慨援助

违法事实

A Novel Nonsense Mutation c.374C>G in CYP21A2 Gene of a Vietnamese Patient with Congenital Adrenal ort a case of an infant who were diagnosed with CAH and presented with the severe phenotype of CAH with symptoms such as increased testicular volume, elevated of 17-hydroxyprogesteron, testosterone and progesterone. In this study, we established an assay for the detection of unusual genetic in the .

巨大没有

CEDE

Synthesis and Characterization of PLGA-PEG Thymoquinone Nanoparticles and Its Cytotoxicity Effects One of the extensively studied compounds is thymoquinone (TQ), and this work aims to compare two types of TQ-nanoformulation and its cytotoxicity toward resistant breast cancer cells..: TQ-nanoparticles were prepared and optimized by using two different formulations with different drugs to PLGA-PEG

Iniquitous

Iniquitous

Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoth ligand-1 (PD-L1), thymidylate synthase (TYMS), and deleted in colorectal cancer (DCC) biomarkers including their roles in the pathophysiology of CRC – has led to their applications in diagnostic and chemo-pharmaceutics. We investigated whether PD-L1, TYMS, and DCC protein expression in CRC tumors

缓解

妈妈不开心

Mariana Abuhamad,Michelle Costa Soaresn the context of clinical outcomes and adverse effects. In NSCLC, compared to CAR-T cells, CIK cells show relatively stronger antitumor efficacy and lower adverse effects. More clinical studies are needed to further confirm the clinical efficiency of both types of cellular immunotherapy.

myriad

Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Celn the context of clinical outcomes and adverse effects. In NSCLC, compared to CAR-T cells, CIK cells show relatively stronger antitumor efficacy and lower adverse effects. More clinical studies are needed to further confirm the clinical efficiency of both types of cellular immunotherapy.